Keith Flaherty, William Hait, Nina Bhardwaj, Dana Pe’er, and Marcia Cruz-Correa forecast what advances to expect in cancer research...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
The countdown to the new year is nearly upon us, but no need to count down to the last...
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast...
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged...
At SABCS 2025, studies show some patients with early-stage breast cancer can skip steps like SLNB or MRI without...
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality...
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with...
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent...
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.